FDA said it’s moving to restrict copycat GLP-1 ingredients used in mass-marketed compounded weight loss drugs, calling out companies including $HIMS & Hers. The agency said compounded products can’t be marketed as “generic” or “equivalent” to FDA-approved GLP-1s, and violators could face enforcement actions like seizure or injunction.